TiGenix: Transparency Information
(Thomson Reuters ONE) -
PRESS RELEASE
REGULATED INFORMATION
Transparency Information
Leuven (BELGIUM) - December 29, 2016, 22:01h CET - TiGenix NV (Euronext Brussels
and Nasdaq: TIG) publishes information in accordance with articles 15 and 18 of
the Belgian Law of May 2, 2007 regarding the publication of major holdings in
issuers whose securities are admitted to trading on a regulated market and
including various provisions (the Law) and the Royal Decree of February
14, 2008 regarding the publication of major holdings.
Following the issuance of 46,000,000 new shares on December 20, 2016 (in the
framework of the Nasdaq IPO) and 11,651,778 new shares on December 29, 2016 (EUR
10 million equity investment by Takeda Pharmaceuticals International AG
announced on December 20, 2016), the transparency data have changed as follows
(status on December 29, 2016):
* Information to be published in accordance with Article 15, §1, al. 1 of the
Law
--------------------------------------------------------------------------
Total of the registered capital: EUR 25,995,636.50
--------------------------------------------------------------------------
Total number of securities conferring voting rights: 259,956,365
--------------------------------------------------------------------------
Total number of voting rights (denominator): 259,956,365
--------------------------------------------------------------------------
* Information to be published in accordance with Article 15, §1, al. 2 of the
Law
Total number of rights (materialized or not in financial instruments) to
subscribe to yet unissued financial instruments that are treated as securities
conferring voting rights: 9,948,165 granted and outstanding warrants which, in
case they are all exercised, give rise to a total number of 9,948,165 voting
rights.
Total number of bonds convertible into securities conferring voting rights: 250
bonds which, in case they are all converted at the current conversion price of
EUR 0.8983 per share, give rise to a total number of 27,830,346 voting rights.
TiGenix NV has not issued any other rights to subscribe to securities conferring
voting rights or any securities without voting rights.
* Information to be published in accordance with Article 18, §1 of the Law
Each physical or legal person acquiring or transferring TiGenix' shares is
required to notify the Belgian Financial Services and Markets Authority (FSMA)
and TiGenix NV each time their shareholding crosses a threshold of three percent
(3%) of the total number of voting securities (the denominator) (upwards or
downwards). Such notification is also required when the threshold of five
percent (5%) or a multiple of five percent (5%) is crossed.
Complete information regarding this requirement can be found in Article 14 of
the articles of association of TiGenix NV.
Notifications must be submitted to both the FSMA and TiGenix NV.
To the FSMA:
* by e-mail: trp.fin(at)fsma.be, and
* a signed copy (for reasons of legal certainty) by fax: +32 2 220 59 12
A copy of the notification must also be sent to TiGenix NV for the attention of
Claudia D'Augusta, CFO:
* by e-mail: investor(at)tigenix.com, and
* a signed copy (for reasons of legal certainty) by fax: +32 16 39 79 70
For submitting the notifications, the FSMA recommends to use its standard form
TR-1BE that is available on the FSMA website
(http://www.fsma.be/en/supervision/fm/gv/ah/circmedprak.aspx) or can be
requested by e-mail with TiGenix NV: investor(at)tigenix.com.
Detailed information regarding the transparency legislation can be found on the
website of the FSMA.
For more information
TiGenix
Claudia D'Augusta
Chief Financial Officer
T: +34 91 804 92 64
claudia.daugusta(at)tigenix.com
About TiGenix
TiGenix NV (Euronext Brussels and Nasdaq: TIG) is an advanced biopharmaceutical
company focused on developing and commercializing novel therapeutics from its
proprietary platforms of allogeneic, or donor-derived, expanded stem cells. Our
lead product candidate from the adipose-derived stem cell technology platform is
Cx601, which is in registration with the European Medicines Agency for the
treatment of complex perianal fistulas in Crohn's disease patients. Our adipose-
derived stem cell product candidate Cx611 has completed a Phase I sepsis
challenge trial and a Phase I/II trial in rheumatoid arthritis. Effective July
31, 2015, TiGenix acquired Coretherapix, whose lead cellular product candidate,
AlloCSC-01, is currently in a Phase II clinical trial in Acute Myocardial
Infarction (AMI). In addition, the second product candidate from the cardiac
stem cell-based platform acquired from Coretherapix, AlloCSC-02, is being
developed in a chronic indication. On July 4, 2016, TiGenix entered into a
licensing agreement with Takeda, a large pharmaceutical company active in
gastroenterology, under which Takeda acquired the exclusive right to
commercialize Cx601 for complex perianal fistulas outside the United States.
TiGenix is headquartered in Leuven (Belgium) and has operations in Madrid
(Spain).
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: TiGenix via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 29.12.2016 - 22:01 Uhr
Sprache: Deutsch
News-ID 515234
Anzahl Zeichen: 6491
contact information:
Town:
Leuven
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 293 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"TiGenix: Transparency Information"
steht unter der journalistisch-redaktionellen Verantwortung von
TiGenix (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
